%0 Journal Article
%A Völker, Lotta
%A Müller-Jensen, Leonie
%A Carl, Sophia
%A Nay, Sandra
%A Möllenkamp, Thiemo Malte
%A Schultze-Florey, Christian
%A Grote-Levi, Lea
%A Jendretzky, Konstantin F
%A Konen, Franz Felix
%A Könecke, Christian
%A Eder, Matthias
%A Panagiota, Victoria
%A Heidel, Florian H
%A Bullinger, Lars
%A Damm, Frederik
%A Frick, Mareike
%A Penack, Olaf
%A Ludwig, Rebecca
%A Buß, Eric Anil
%A Boehmerle, Wolfgang
%A Endres, Matthias
%A Gudi, Viktoria
%A Huehnchen, Petra
%A Skripuletz, Thomas
%A Möhn, Nora
%T The Berlin-Hannover ICANS severity assessment-a novel bedside test to evaluate CAR T-cell-associated neurotoxicity.
%J Frontiers in neurology
%V 17
%@ 1664-2295
%C Lausanne
%I Frontiers Research Foundation
%M DZNE-2026-00176
%P 1726779
%D 2026
%X Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory hematological malignancies but is frequently complicated by immune effector cell-associated neurotoxicity syndrome (ICANS). Early clinical recognition remains challenging, as the commonly used Immune Effector Cell-Associated Encephalopathy (ICE) score lacks sensitivity for subtle deficits.In this prospective bicentric study, 100 patients treated with CAR T-cells at Hannover Medical School and Charité - Universitätsmedizin Berlin underwent systematic neurological assessments using both ICE and the newly developed Berlin-Hannover ICANS Severity Assessment (BHISA). Examinations were performed at baseline prior to CAR T-cell infusion, on day 6-7 (±1 day) post-infusion, and during ICANS episodes. Data on the clinical course, other toxicities, comorbidities, CAR T-cell products, and ICANS treatment were collected.Thirty-seven patients (37
%K BHISA (Other)
%K CAR T-cell therapy (Other)
%K ICANS (Other)
%K ICE (Other)
%K screening tools (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41648666
%2 pmc:PMC12867840
%R 10.3389/fneur.2026.1726779
%U https://pub.dzne.de/record/285052